Christopher Poole - Concepedia

Author

Christopher Poole

Also Known As

C Caldas, C J Poole, C Poole, C. J. Poole, C. Poole, C.J. Poole, Christopher J Poole, Christopher J. Poole, Christopher John Poole, Christopher Poole

126

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

University of Birmingham University of Warwick Edinburgh Cancer Research University College London Cancer Research UK Clinical Trials Unit

About

Christopher Poole is an author at University of Birmingham specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	3.6K
2	Health Sciences	4	4	1.6K
3	Engineering	1	1	29
4	Public Health	1	1	42
5	Biostatistics	1	1	14

Christopher Poole

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D) Annie Young, Andrea Marshall, Jenny Thirlwall, Journal of Clinical Oncology Vte RecurrencePathologyPharmacotherapyThrombosisLow Vte Recurrence	2018	1.3K
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, The Lancet Oncology MedicineRandomised Phase 2GynecologyCancer TreatmentOncology	2014	540
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Richard Gray, Daniel Rea, Kelly Handley, Journal of Clinical Oncology Breast OncologyCancer ManagementEpidemiology Of CancerGynecologyPharmacotherapy	2013	446
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial Mothaffar F. Rimawi, Jean-Marc Ferrero, Juan de la Haba-Rodríguez, Journal of Clinical Oncology	2018	213
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others John M.S. Bartlett, Jane Bayani, Andrea Marshall, JNCI Journal of the National Cancer Institute	2016	210
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer Syed A. Hussain, Raji Ganesan, Gary Reynolds, British Journal of Cancer	2007	193
Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer Christopher Poole, Helena Earl, Louise Hiller, New England Journal of Medicine	2006	189
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial Peter Barrett‐Lee, Lindsay Johnson, David Cameron, The Lancet Breast OncologyOncologyPhase IiiClinical TrialsAdjuvant Chemotherapy	2009	188
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer Ian S. Fentiman, Christopher Poole, David Tong, European Journal of Cancer Radiation MedicineBreast OncologyRadiation TherapyIridium ImplantMedicine	1996	177
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse Ignace Vergote, Deborah K. Armstrong, Giovanni Scambia, Journal of Clinical Oncology	2016	149

Page 1